ReviewBritish journal of anaesthesia2014
Cryoprecipitate therapy.
Review in British journal of anaesthesia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 200 citations in OpenAlex.
- Treatment effects of fibrinogen concentrates vs. cryoprecipitate for correcting hypofibrinogenemia in cardiac surgery patients: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2025Pooled it
- Efficacy of fibrinogen concentrate in major abdominal surgery - A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei.Journal of thrombosis and haemostasis : JTH · 2020Trial
- Trial
- Fibrinogen Early In Severe Trauma studY (FEISTY): study protocol for a randomised controlled trial.Trials · 2017Trial
- Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy.British journal of anaesthesia · 2016Trial
- Fibrinogen Concentrate in Acute Hemorrhage: Mechanistic Insight, Thresholds, and Targeted Replacement.Journal of clinical medicine · 2026Review
- Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies.Cureus · 2026Article
- Cryoprecipitate utilization in the neonatal intensive care unit: a single-center review.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Article
- Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex.Transfusion · 2026Article
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Article
- Article
- Comparison of Hemostatic Activity in Canine Leukoreduced Cryoprecipitate, Cryopoor Plasma, and Fresh Plasma.Veterinary clinical pathology · 2025Article
- Management of the acute on chronic liver failure in the intensive care unit.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Hemostats in the clinic.Bioengineering & translational medicine · 2024Review
- Rare inherited coagulation disorders: no longer orphan and neglected.Research and practice in thrombosis and haemostasis · 2024Review
- The Evolution of Hemophilia Therapeutics: An Illustrated Review.Research and practice in thrombosis and haemostasis · 2024Article
- The incidence, risk factors, and prognosis of acute kidney injury in patients after cardiac surgery.Frontiers in cardiovascular medicine · 2024Article
- Hemostatic capability of ultrafiltrated fresh frozen plasma compared to cryoprecipitate.Scientific reports · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryoprecipitate, originally developed as a therapy for patients with antihaemophilic factor deficiency, or haemophilia A, has been in use for almost 50 yr. However, cryoprecipitate is no longer administered according to its original purpose, and is now most commonly used to replenish fibrinogen levels in patients with acquired coagulopathy, such as in clinical settings with haemorrhage including cardiac surgery, trauma, liver transplantation (LT), or obstetric haemorrhage. Cryoprecipitate is a pooled product that does not undergo pathogen inactivation, and its administration has been associated with a number of adverse events, particularly transmission of blood-borne pathogens and transfusion-related acute lung injury. As a result of these safety concerns, along with emerging availability of alternative fibrinogen preparations, cryoprecipitate has been withdrawn from use in a number of European countries. Compared with the plasma from which it is prepared, cryoprecipitate contains a high concentration of coagulation factor VIII, coagulation factor XIII, and fibrinogen. Cryoprecipitate is usually licensed by regulatory authorities for the treatment of hypofibrinogenaemia, and recommended for supplementation when plasma fibrinogen levels decrease below 1 g litre(-1); however, this threshold is empiric and is not based on solid clinical evidence. Consequently, there is uncertainty over the appropriate dosing and optimal administration of cryoprecipitate, with some guidelines from professional societies to guide clinical practice. Randomized, controlled trials are needed to determine the clinical efficacy of cryoprecipitate, compared with the efficacy of alternative preparations. These trials will allow the development of evidence-based guidelines in order to inform physicians and guide clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.